NCT04827576

Study of Magrolimab in Patients With Solid Tumors

A Phase 2, Multi-Arm Study of Magrolimab in Patients With Solid Tumors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with docetaxel in participants with solid tumors.

Detailed description

This study will consist of a Safety Run-in Cohort 1 (magrolimab + docetaxel combination). After completion of the Safety Run-in Cohort 1, Phase 2 Cohort 1 will occur as follows: * Phase 2 Cohort 1: a cohort of participants with solid tumors (metastatic non-small cell lung cancer (mNSCLC) (Phase 2 Cohort 1a), metastatic urothelial cancer (mUC) (Phase 2 Cohort 1b), and metastatic small cell lung cancer (mSCLC) (Phase 2 Cohort 1c).

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	Magrolimab	Administered intravenously
DRUG	Docetaxel	Administered intravenously

Timeline

• Start date: 2021-10-01
• Primary completion: 2024-10-01
• Completion: 2024-10-01
• First posted: 2021-04-01
• Last updated: 2025-05-08
• Results posted: 2025-05-08

Locations

49 sites across 5 countries: United States, France, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study